Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Bywater MJ, Poortinga G, Sanij E, Hein N, Peck A, Cullinane C, Wall M, Cluse L, Drygin D, Anderes K, Huser N, Proffitt C, Bliesath J, Haddach M, Schwaebe MK, Ryckman DM, Rice WG, Schmitt C, Lowe SW, Johnstone RW, Pearson RB, McArthur GA, Hannan RD. Bywater MJ, et al. Among authors: cluse l. Cancer Cell. 2012 Jul 10;22(1):51-65. doi: 10.1016/j.ccr.2012.05.019. Cancer Cell. 2012. PMID: 22789538 Free PMC article.
Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737.
Wiegmans AP, Alsop AE, Bots M, Cluse LA, Williams SP, Banks KM, Ralli R, Scott CL, Frenzel A, Villunger A, Johnstone RW. Wiegmans AP, et al. Among authors: cluse la. Cancer Res. 2011 May 15;71(10):3603-15. doi: 10.1158/0008-5472.CAN-10-3289. Epub 2011 Mar 11. Cancer Res. 2011. PMID: 21398407 Free article.
The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.
Ellis L, Bots M, Lindemann RK, Bolden JE, Newbold A, Cluse LA, Scott CL, Strasser A, Atadja P, Lowe SW, Johnstone RW. Ellis L, et al. Among authors: cluse la. Blood. 2009 Jul 9;114(2):380-93. doi: 10.1182/blood-2008-10-182758. Epub 2009 Apr 21. Blood. 2009. PMID: 19383971 Free PMC article.
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.
Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L, Williams S, Wiegmans AP, Dear AE, Scott CL, Pellegrini M, Wei A, Richon VM, Marks PA, Lowe SW, Smyth MJ, Johnstone RW. Lindemann RK, et al. Among authors: cluse la. Proc Natl Acad Sci U S A. 2007 May 8;104(19):8071-6. doi: 10.1073/pnas.0702294104. Epub 2007 Apr 30. Proc Natl Acad Sci U S A. 2007. PMID: 17470784 Free PMC article.
Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
Newbold A, Matthews GM, Bots M, Cluse LA, Clarke CJ, Banks KM, Cullinane C, Bolden JE, Christiansen AJ, Dickins RA, Miccolo C, Chiocca S, Kral AM, Ozerova ND, Miller TA, Methot JL, Richon VM, Secrist JP, Minucci S, Johnstone RW. Newbold A, et al. Among authors: cluse la. Mol Cancer Ther. 2013 Dec;12(12):2709-21. doi: 10.1158/1535-7163.MCT-13-0626. Epub 2013 Oct 3. Mol Cancer Ther. 2013. PMID: 24092806
BET Inhibition Enhances TNF-Mediated Antitumor Immunity.
Wellinger LC, Hogg SJ, Newman DM, Friess T, Geiss D, Michie J, Ramsbottom KM, Bacac M, Fauti T, Marbach D, Jarassier L, Thienger P, Paehler A, Cluse LA, Kearney CJ, Vervoort SJ, Trapani JA, Oliaro J, Shortt J, Ruefli-Brasse A, Rohle D, Johnstone RW. Wellinger LC, et al. Among authors: cluse la. Cancer Immunol Res. 2022 Jan;10(1):87-107. doi: 10.1158/2326-6066.CIR-21-0224. Epub 2021 Nov 15. Cancer Immunol Res. 2022. PMID: 34782346
25 results